+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 15Years - 99Years
All Genders
ID06497465

Evaluating Dolutegravir and Lamivudine Dual Therapy Compared to Standard Three-Drug ART in People with HIV and Tuberculosis Receiving Rifampin-Based Treatment

Led by Johns Hopkins University · Updated on 2026-09-11

150

Participants Needed

5

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effectiveness, safety, and tolerability of different antiretroviral therapy ART regimens in people with HIV-1 who are also receiving rifampin-based treatment for tuberculosis TB. This Phase IIIb international trial compares two dual therapy regimens using dolutegravir and lamivudine with the standard three-drug ART regimen in individuals who have not previously received ART. The study addresses the high global burden of TB among people with HIV and explores starting ART alongside TB treatment to improve survival. Participants will be randomly assigned to one of three groups Arm 1 receives a twice-daily fixed-dose combination of dolutegravir 50mg and lamivudine 300mg during TB therapy and for two weeks after, then once daily up to week 52 Arm 2 receives the same combination once daily in the morning plus dolutegravir 50mg in the evening during TB therapy and for two weeks after, then once daily to week 52 Arm 3 follows the local standard of care with dolutegravir 50mg plus tenofovir disoproxil fumaratelamivudine once daily during and after TB therapy. Treatment continues for 52 weeks in all arms. During the study, participants will have their HIV viral load and CD4 cell counts monitored at 28 and 48 weeks to assess virologic suppression and immune response. Additional evaluations include measuring drug concentrations and monitoring adverse events over two years. The primary outcome is the proportion of participants achieving HIV-1 virologic suppression at 28 weeks. The trial involves regular visits and medical assessments to ensure safety and treatment adherence throughout the study period.

CONDITIONS

Brief Title

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Research Team

B

Beatriz M Kohler, RN

K

Kate Boehner, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here